Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry Yang

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|February 26, 2020
Steroidogenic Factor 1 (NR5A1) Activates ATF3 Transcriptional ActivityNatsuko Emura, Chiung-Min Wang, William Harry Yang, et al.
Human Vaccines & Immunotherapeutics|June 19, 2018
Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive populationLi Yu, Mark T Esser, Judith Falloon, et al.
Journal of Biopharmaceutical Statistics|October 31, 2014
Non-normal random effects models for immunogenicity assay cut point determinationJianchun Zhang, Binbing Yu, Lanju Zhang, et al.
Journal of Immunological Methods|October 13, 2018
Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessmentsRobert J Kubiak, Jianchun Zhang, Pin Ren, et al.
Journal of Biopharmaceutical Statistics|October 31, 2014
Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statisticSteven Novick, Yan Shen, Harry Yang, et al.
COPD|October 12, 2013
Clinical trial simulation to assist in COPD trial planning and design with a biomarker-based diagnostic: when to pull the trigger?David L Gold, Michelle Dawson, Harry Yang, et al.
Journal of Biomolecular Screening|February 5, 2014
A New Bliss Independence Model to Analyze Drug Combination DataWei Zhao, Kris Sachsenmeier, Lanju Zhang, et al.
Pediatric Transplantation|August 13, 2009
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host diseaseJoel A Brochstein, Stephan Grupp, Harry Yang, et al.
Pharmaceutical Statistics|August 17, 2018
Effect of a statistical outlier in potency bioassaysPerceval Sondag, Lingmin Zeng, Binbing Yu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 19, 2003
Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infantsShelah Leader, Harry Yang, John DeVincenzo, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|February 26, 2020
Steroidogenic Factor 1 (NR5A1) Activates ATF3 Transcriptional ActivityNatsuko Emura, Chiung-Min Wang, William Harry Yang, et al.
Human Vaccines & Immunotherapeutics|June 19, 2018
Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive populationLi Yu, Mark T Esser, Judith Falloon, et al.
Journal of Biopharmaceutical Statistics|October 31, 2014
Non-normal random effects models for immunogenicity assay cut point determinationJianchun Zhang, Binbing Yu, Lanju Zhang, et al.
Journal of Immunological Methods|October 13, 2018
Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessmentsRobert J Kubiak, Jianchun Zhang, Pin Ren, et al.
Journal of Biopharmaceutical Statistics|October 31, 2014
Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statisticSteven Novick, Yan Shen, Harry Yang, et al.
COPD|October 12, 2013
Clinical trial simulation to assist in COPD trial planning and design with a biomarker-based diagnostic: when to pull the trigger?David L Gold, Michelle Dawson, Harry Yang, et al.
Journal of Biomolecular Screening|February 5, 2014
A New Bliss Independence Model to Analyze Drug Combination DataWei Zhao, Kris Sachsenmeier, Lanju Zhang, et al.
Pediatric Transplantation|August 13, 2009
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host diseaseJoel A Brochstein, Stephan Grupp, Harry Yang, et al.
Pharmaceutical Statistics|August 17, 2018
Effect of a statistical outlier in potency bioassaysPerceval Sondag, Lingmin Zeng, Binbing Yu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 19, 2003
Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infantsShelah Leader, Harry Yang, John DeVincenzo, et al.
Pageof 6